- Home
- MED vs HURA Comparison
MED vs HURA Comparison
Compare MED & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- HURA
- Stock Information
- Founded
- MED 1980
- HURA 2009
- Country
- MED United States
- HURA United States
- Employees
- MED N/A
- HURA N/A
- Industry
- MED Packaged Foods
- HURA
- Sector
- MED Consumer Staples
- HURA
- Exchange
- MED Nasdaq
- HURA Nasdaq
- Market Cap
- MED 152.3M
- HURA 122.0M
- IPO Year
- MED N/A
- HURA N/A
- Fundamental
- Price
- MED $13.20
- HURA $3.06
- Analyst Decision
- MED Hold
- HURA Strong Buy
- Analyst Count
- MED 1
- HURA 2
- Target Price
- MED $16.50
- HURA $11.50
- AVG Volume (30 Days)
- MED 207.8K
- HURA 778.4K
- Earning Date
- MED 08-04-2025
- HURA 08-14-2025
- Dividend Yield
- MED N/A
- HURA N/A
- EPS Growth
- MED N/A
- HURA N/A
- EPS
- MED 0.33
- HURA N/A
- Revenue
- MED $480,449,000.00
- HURA N/A
- Revenue This Year
- MED N/A
- HURA N/A
- Revenue Next Year
- MED N/A
- HURA N/A
- P/E Ratio
- MED $39.98
- HURA N/A
- Revenue Growth
- MED N/A
- HURA N/A
- 52 Week Low
- MED $11.57
- HURA $1.80
- 52 Week High
- MED $21.98
- HURA $8.63
- Technical
- Relative Strength Index (RSI)
- MED 44.86
- HURA N/A
- Support Level
- MED $12.90
- HURA N/A
- Resistance Level
- MED $13.84
- HURA N/A
- Average True Range (ATR)
- MED 0.60
- HURA 0.00
- MACD
- MED -0.05
- HURA 0.00
- Stochastic Oscillator
- MED 22.67
- HURA 0.00
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.